ReNeuron Group ( ) - 株価, ニュースと分析AIM:RENE

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

RENE 株式概要

Researches, develops, and commercializes cell-based therapies in the United Kingdom.

会社概要

RENE ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	4/6
配当金	0/6

報酬

過去5年間の収益は年間17.8%増加しました。

リスク分析

キャッシュランウェイが1年未満である

株式の流動性は非常に低い

収益が 100 万ドル未満 ( £249K )

意味のある時価総額がありません ( £2M )

ReNeuron Group plc 競合他社

ProBiotix Health

OFEX:PBX

UK£5.2m

Aptamer Group

AIM:APTA

UK£4.5m

Roquefort Therapeutics

LSE:ROQ

UK£4.6m

Theracryf

AIM:TCF

UK£3.2m

価格と性能

の歴代最高値、変動、値下がりまとめReNeuron Group
過去の株価
現在の株価	UK£0.034
52週高値	UK£0.11
52週安値	UK£0.033
ベータ	0.69
11ヶ月の変化	0%
3ヶ月変化	-2.17%
1年変化	-58.59%
33年間の変化	-97.71%
5年間の変化	-98.75%
IPOからの変化	-99.87%

Recent updates

株主還元

	RENE	GB Biotechs	GB 市場
7D	0%	4.7%	1.4%
1Y	-58.6%	-16.4%	8.1%

業界別リターン: RENE過去 1 年間で-27 % の収益を上げたUK Biotechs業界を下回りました。

リターン対市場: RENEは、過去 1 年間で5.4 % のリターンを上げたUK市場を下回りました。

価格変動

Is RENE's price volatile compared to industry and market?
RENE volatility
RENE Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.0%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.5%
10% least volatile stocks in GB Market	2.5%

安定した株価: RENE過去 3 か月間に大きな価格変動はありませんでした。

時間の経過による変動: 過去 1 年間のRENEのボラティリティの変化を判断するにはデータが不十分です。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
1997	26	n/a	www.reneuron.com

ReNeuron Group plc 基礎のまとめ

ReNeuron Group の収益と売上を時価総額と比較するとどうか。
RENE 基礎統計学
時価総額	UK£1.93m
収益（TTM）	-UK£5.07m
売上高(TTM)	UK£249.00k

7.7x

P/Sレシオ

-0.4x

PER（株価収益率

RENE は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
RENE 損益計算書（TTM）
収益	UK£249.00k
売上原価	UK£3.65m
売上総利益	-UK£3.40m
その他の費用	UK£1.67m
収益	-UK£5.07m

直近の収益報告

Sep 30, 2023

次回決算日

May 30, 2024

一株当たり利益（EPS）	-0.089
グロス・マージン	-1,367.47%
純利益率	-2,037.35%
有利子負債／自己資本比率	0%

RENE の長期的なパフォーマンスは？

過去の実績と比較を見る

This company listing is no longer active

RENE 株式概要

報酬

リスク分析

ReNeuron Group plc 競合他社

OFEX:PBX

UK£5.2m

AIM:APTA

UK£4.5m

LSE:ROQ

UK£4.6m

AIM:TCF

UK£3.2m

価格と性能

最新ニュース

ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024

ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024

ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024

Consensus revenue estimates decrease by 28%, EPS upgraded

New minor risk - Profitability

ReNeuron Group plc to Report First Half, 2024 Results on Nov 09, 2023

Recent updates

ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024

ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024

ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024

Consensus revenue estimates decrease by 28%, EPS upgraded

New minor risk - Profitability

ReNeuron Group plc to Report First Half, 2024 Results on Nov 09, 2023

ReNeuron Group plc, Annual General Meeting, Aug 22, 2023

Consensus EPS estimates upgraded to UK£0.10 loss

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReNeuron Group plc to Report Q4, 2023 Results on May 25, 2023

High number of new and inexperienced directors

ReNeuron Group plc Appoints Iain Ross as Executive Chairman

Consensus forecasts updated

First half 2023 earnings released: UK£0.056 loss per share (vs UK£0.092 loss in 1H 2022)

No longer forecast to breakeven

Less than half of directors are independent

Less than half of directors are independent

ReNeuron Group plc Appoints John Hawkins as Chief Financial Officer

Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)

ReNeuron Group plc, Annual General Meeting, Sep 09, 2022

ReNeuron Group plc, Annual General Meeting, Sep 09, 2022

ReNeuron Group plc Announces Appointment of Catherine Isted as Chief Executive Officer, Effective 1 September 2022

We Think ReNeuron Group (LON:RENE) Needs To Drive Business Growth Carefully

Price target decreased to UK£2.22

Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)

ReNeuron Group plc to Report Fiscal Year 2022 Results on Jul 04, 2022

Price target decreased to UK£2.19

ReNeuron Group plc, Annual General Meeting, Jul 14, 2022

Price target decreased to UK£2.04

ReNeuron Group plc Announces CEO Changes, Effective 28 February 2022

ReNeuron Group plc Announces Leaving of Olav Hellebø as Executive Director

We're Keeping An Eye On ReNeuron Group's (LON:RENE) Cash Burn Rate

Price target decreased to UK£2.04

First half 2022 earnings: EPS and revenues miss analyst expectations

Companies Like ReNeuron Group (LON:RENE) Can Afford To Invest In Growth

Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)

Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)

Will ReNeuron Group (LON:RENE) Spend Its Cash Wisely?

ReNeuron Group plc Announces Resignation of Michael Hunt, Chief Financial Officer

Is ReNeuron Group (LON:RENE) In A Good Position To Deliver On Growth Plans?

New 90-day high: UK£1.11

New 90-day low: UK£0.72

First half 2021 earnings released: UK£0.22 loss per share

New 90-day low: UK£0.78

Here's What We Learned About The CEO Pay At ReNeuron Group plc (LON:RENE)

ReNeuron Group plc to Report First Half, 2021 Results on Nov 10, 2020

New 90-day low: UK£0.85

Analysts update estimates

ReNeuron Group plc Auditor Raises 'Going Concern' Doubt

Full year earnings released - UK£0.36 loss per share

New 90-day low - UK£1.08

New 90-day low - UK£1.22

株主還元

価格変動

会社概要

ReNeuron Group plc 基礎のまとめ

7.7x

-0.4x